Skip to content

Aaron S. Wolfgang

3 papers in the library · 11 citations · publishing 2021-2025

Papers

Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.

Am J Psychiatry January 1, 2025 Aaron S. Wolfgang, Vetisha L. McClair, Paula P. Schnurr et al. 6 citations

The Veterans Health Administration (VHA) is exploring the integration of psychedelic-assisted therapy as a potential treatment for veterans with mental health conditions, particularly PTSD. The text outlines the need for careful research and implementation strategies within the VHA system, emphasizing safe integration, care pathways, and the development of clinical protocols. It highlights the importance of addressing regulatory, ethical, and logistical challenges to ensure veteran well-being and recovery. The work suggests that psychedelic-assisted therapies could offer innovative treatment options, but rigorous study and structured implementation are necessary before widespread adoption.

Any Questions? A Sober Look at MDMA.

Biol Psychiatry August 1, 2021 Luke G. Petry, Monica Sharma, Aaron S. Wolfgang et al. 4 citations

The text critically examines the use of MDMA in therapeutic contexts, arguing that the current enthusiasm for MDMA-assisted therapy may overlook significant risks and methodological shortcomings. It questions the robustness of evidence supporting its efficacy for conditions like PTSD, highlighting issues such as small sample sizes, lack of long-term safety data, and potential for adverse effects. The author suggests that a sober, evidence-based evaluation is necessary before embracing MDMA as a treatment, emphasizing the need for rigorous research and caution against premature adoption.

MDMA-assisted therapy for borderline personality disorder

Journal of Psychedelic Studies December 14, 2023 Ann M. Inouye, Aaron S. Wolfgang, Lianne T. Philhower 1 citation

Borderline personality disorder (BPD) is often misunderstood, misdiagnosed, and stigmatized, with 25–58% of individuals also having post-traumatic stress disorder (PTSD). In Phase 3 clinical trials, up to 71.2% of full-dose MDMA participants for treatment-resistant PTSD no longer met PTSD criteria. This qualitative study interviewed two clinicians treating BPD and two MDMA-assisted therapy clinicians, exploring overlaps in etiology and conceptualization. Through eight interviews, perspectives revealed similarities and limitations of both dialectical behavioral therapy and MDMA-assisted therapy.